Table 4.
All pipelines’ (KRSA, UKA, PTM-SEA, and KEA3) weighted average percentile rankings.
| Cell Line | Rank | Kinase | Family | Weighted Average | KRSA | UKA | PTM-SEA | KEA3 |
|---|---|---|---|---|---|---|---|---|
| PANC1 | #1 | SRC | SRC | 82% | 91% | 92% | 55% | 91% |
| PANC1 | #2 | FYN | SRC | 81% | 91% | 88% | 68% | 78% |
| PANC1 | #3 | INSR | INSR | 75% | 70% | 64% | 95% | 72% |
| PANC1 | #4 | ABL1 | ABL | 75% | 87% | 95% | 36% | 82% |
| PANC1 | #5 | LCK | SRC | 71% | 91% | 100% | 9% | 85% |
| PANC1 | #6 | PDGFRA | PDGFR | 70% | 83% | 91% | 9% | 97% |
| PANC1 | #7 | TXK | TEC | 67% | 100% | 77% | - | 90% |
| PANC1 | #8 | RET | RET | 67% | 26% | 77% | 77% | 87% |
| PANC1 | #9 | EPHA2 | EPH | 65% | 30% | 59% | 91% | 81% |
| PANC1 | #10 | SRMS | SRC | 64% | 91% | 85% | - | 81% |
| PDCL15 | #1 | SRC | SRC | 90% | 96% | 92% | 82% | 90% |
| PDCL15 | #2 | PDGFRA | PDGFR | 86% | 87% | 93% | 68% | 97% |
| PDCL15 | #3 | INSR | INSR | 73% | 70% | 57% | 100% | 65% |
| PDCL15 | #4 | LYN | SRC | 72% | 96% | 99% | 59% | 34% |
| PDCL15 | #5 | PDGFRB | PDGFR | 71% | 87% | 65% | 91% | 41% |
| PDCL15 | #6 | LCK | SRC | 70% | 96% | 100% | 0% | 85% |
| PDCL15 | #7 | EPHA2 | EPH | 69% | 74% | 28% | 91% | 82% |
| PDCL15 | #8 | TXK | TEC | 66% | 91% | 80% | - | 92% |
| PDCL15 | #9 | FYN | SRC | 66% | 96% | 91% | 0% | 76% |
| PDCL15 | #10 | MST1R | MET | 64% | 78% | 87% | - | 93% |
| PDCL5 | #1 | ALK | ALK | 70% | 74% | 97% | 63% | 45% |
| PDCL5 | #2 | ZAP70 | SYK | 65% | 52% | 69% | 70% | 70% |
| PDCL5 | #3 | TXK | TEC | 65% | 65% | 100% | - | 95% |
| PDCL5 | #4 | JAK2 | JAK | 65% | 43% | 91% | 53% | 73% |
| PDCL5 | #5 | EGFR | EGFR | 62% | 83% | 58% | 67% | 42% |
| PDCL5 | #6 | KDR | VEGFR | 62% | 91% | 39% | 30% | 89% |
| PDCL5 | #7 | EPHB3 | EPH | 62% | 61% | 88% | - | 98% |
| PDCL5 | #8 | AXL | AXL | 59% | 57% | 28% | 97% | 54% |
| PDCL5 | #9 | CSK | CSK | 59% | 13% | 72% | 87% | 63% |
| PDCL5 | #10 | INSR | INSR | 58% | 78% | 23% | 70% | 61% |
| Patient-Derived | #1 | LCK | SRC | 80% | 96% | 88% | 60% | 78% |
| Patient-Derived | #2 | SRC | SRC | 79% | 96% | 45% | 96% | 81% |
| Patient-Derived | #3 | LYN | SRC | 72% | 96% | 96% | 64% | 32% |
| Patient-Derived | #4 | PDGFRA | PDGFR | 72% | 87% | 53% | 52% | 96% |
| Patient-Derived | #5 | TXK | TEC | 69% | 91% | 99% | - | 85% |
| Patient-Derived | #6 | INSR | INSR | 66% | 83% | 21% | 100% | 60% |
| Patient-Derived | #7 | EGFR | EGFR | 64% | 61% | 41% | 92% | 63% |
| Patient-Derived | #8 | EPHA2 | EPH | 64% | 65% | 39% | 80% | 72% |
| Patient-Derived | #9 | SRMS | SRC | 63% | 96% | 79% | - | 76% |
| Patient-Derived | #10 | EPHB3 | EPH | 58% | 65% | 75% | - | 93% |
| All | #1 | SRC | SRC | 85% | 91% | 76% | 91% | 82% |
| All | #2 | LCK | SRC | 81% | 91% | 99% | 55% | 78% |
| All | #3 | PDGFRA | PDGFR | 75% | 87% | 81% | 36% | 96% |
| All | #4 | LYN | SRC | 72% | 91% | 100% | 59% | 38% |
| All | #5 | TXK | TEC | 70% | 96% | 97% | - | 85% |
| All | #6 | INSR | INSR | 68% | 78% | 32% | 100% | 62% |
| All | #7 | EPHA2 | EPH | 64% | 57% | 43% | 86% | 72% |
| All | #8 | JAK2 | JAK | 64% | 61% | 68% | 64% | 63% |
| All | #9 | SRMS | SRC | 63% | 91% | 84% | - | 76% |
| All | #10 | FYN | SRC | 62% | 91% | 59% | 23% | 74% |